The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Predicting the Future: Prognostication in Rheumatoid Arthritis

Predicting the Future: Prognostication in Rheumatoid Arthritis

July 19, 2022 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

At baseline, these patients underwent MRI of the hands and feet and were evaluated for swollen joint count, positivity for rheumatoid factor and anti-citrullinated protein antibodies (ACPA), and elevation of C-reactive protein. The primary outcome measure was development of RA at one year of follow-up.

You Might Also Like
  • Not Your Average Case: Difficult-to-Treat Rheumatoid Arthritis
  • California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis
  • The Future of Rheumatoid Arthritis Treatment
Explore This Issue
September 2022
Also By This Author
  • Stay the Course: How to Maintain Remission in Vasculitis

The researchers found that tenosynovitis, as seen on MRI in these patients, was independently associated with RA development, especially among patients with the absence of rheumatoid factor and ACPA. In patients without tenosynovitis in oligoarthritis or polyarthritis, essentially no progression to RA was seen.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

These data are helpful in both preventing overtreatment and identifying patients at higher risk of progression to RA, although Dr. den Hollander noted that implementation of such routine use of MRI in real-world clinical practice may be challenging.

Dr. Alivernini

Synovial Tissue Macrophages

In the third lecture, Stefano Alivernini, MD, PhD, consultant in rheumatology, Catholic University of the Sacred Heart, Milan, Italy, talked about the transcriptomic signature of sustained remission in RA as seen in synovial tissue macrophages. Essentially, Alivernini et al. sought to evaluate the histological composition of synovial tissue in RA patients who were in sustained clinical and ultrasound remission.3 The researchers hoped to identify synovial biomarkers that are predictive of disease flares or, conversely, of disease remission using histology, macrophage phenotyping and spatial transcriptomics.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers found that synovial tissue enhancement of macrophages positive for MerTK (a member of the Tyro-AxlMerTK family of receptor tyrosine kinases) was associated with remission maintenance in RA patients in sustained remission after treatment modification.

In addition, digital spatial profiling analysis revealed unique transcriptomic signatures of lining and sublining macrophages in patients in remission that are then associated with subsequent disease flare after treatment modification.

By understanding RA on this molecular level, researchers and clinicians may one day be able to identify features that predict maintenance of remission or high likelihood of relapse of disease.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

2 New Antibodies

Dr. van der Woude

Later in the session, Diane van der Woude, MD, PhD, rheumatologist and head of the Outpatient Clinic, Leiden University Medical Center, the Netherlands, spoke about two new antibodies that may be relevant in patients with seronegative RA. Dr. van der Woude noted that antimalondialdehyde-acetaldehyde (antiMAA) antibodies have, in the past, been described in patients with seropositive and seronegative RA, osteoarthritis, systemic lupus erythematosus and a number of cardiovascular diseases.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: anti-advanced glycated end-products (anti-AGE) antibodies, anti-malondialdehyde-acetaldehyde (anti-MAA) antibodies, EULAR, EULAR 2022, RA Resource Center, Rheumatoid Arthritis (RA), synovial, TenosynovitisIssue: September 2022

You Might Also Like:
  • Not Your Average Case: Difficult-to-Treat Rheumatoid Arthritis
  • California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis
  • The Future of Rheumatoid Arthritis Treatment
  • Tissue Evaluation: Understanding Rheumatoid Arthritis Inside & Out

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)